- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Living Life With Metastatic Breast Cancer From a Male Perspective
In this episode of Managed Care Cast, we speak with a male patient with breast cancer who was diagnosed with metastatic disease in 2016 about how he lives his life and what he wants people to know about this rare cancer.
Metastatic breast cancer is the most advanced stage of breast cancer; it is treatable but not curable. Men with breast cancer comprise less than 1% of all patients with the disease, and most of their treatments are based on study results seen among female patients. This year alone, experts predict that 276,480 women and 2620 men will receive a breast cancer diagnosis.
The American Journal of Managed Care® spoke recently with Kirby Lewis of West Virginia. Kirby was a stage 2 breast cancer survivor, for which he had a mastectomy in 2012, prior to receiving a diagnosis of metastatic breast cancer (MBC) in 2016. He is 1 of 9 patients with MBC who serve as representatives of “Facing MBC Together” from Athenex Oncology.
In this interview, he describes his philosophy about living life to the fullest and what he wants people to know about male breast cancer.
Listen above or through one of these podcast services:
Racial Inequities in Guideline-Adherent Breast Cancer Care and Timely Treatment
November 19th 2024Older non-Hispanic Black adults with early-stage breast cancer are less likely to receive timely treatment and guideline-concordant care, increasing their risk of death compared with non-Hispanic White women.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Advancing Breast Cancer Care With HER2-Targeted Therapies
October 10th 2024In this interview from our Institute for Value-Based Medicine® event in Boston, we speak with Michael Hassett, MD, MPH, Dana-Farber Cancer Institute, on the clinical significance and cost implications of HER2 in the breast cancer space.
Read More
Managing Germline Mutations in Hereditary Breast Cancer Risk
October 7th 2024Hereditary breast cancers are caused by germline mutations, which are genetic mutations inherited at conception and so called because they originate in germ cells, those that develop into reproductive cells and become eggs in female individuals and sperm in male individuals.
Read More
